Study of the COMS One Device to Treat Long-Lasting Diabetic Foot Ulcers in Adults Aged 22 to 90
Led by Piomic Medical · Updated on 2026-02-17
450
Participants Needed
30
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the COMS One device in treating people with refractory diabetic foot ulcers DFUs. This prospective randomized, double-blinded, sham-controlled clinical trial aims to show that the COMS One device, used alongside standard care, can better promote wound closure compared to a sham device over 24 weeks. The main goal is to measure the time until complete wound healing, defined by full skin re-epithelialization without drainage.
The study involves two groups one receiving the COMS One device and the other a sham device. Both devices include a reusable housing with controls and magnetic stimulation coils, a single-use sterile base called COMStouch, and a single-use strap called COMSfix to hold the device in place. Treatments are applied locally and participants continue standard wound care. The study plans to enroll 224 subjects after screening up to 450, with treatments lasting up to 24 weeks.
Participants will attend regular visits to assess wound healing progress, safety, pain levels, and quality of life. Researchers will measure wound closure at multiple timepoints up to 24 weeks and monitor for adverse events, ulcer recurrence, and any need for amputation. The study includes careful monitoring of wound area reduction and participant-reported outcomes to evaluate the devices performance and safety throughout the trial.
CONDITIONS
Brief Title
Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers
Research Team
R
Rejelle Williams
B
Bernard Laurel
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Investigational COMS One device
Sham device
Standard multidisciplinary wound care (context)
What it is
A portable device delivering combined optical (red and near‑infrared LEDs) and magnetic stimulation through a disposable applicator and strap
A similarly appearing device that lacks the therapeutic optical and magnetic outputs but maintains blinding
Established multidisciplinary care including wound debridement, offloading, infection management, vascular and metabolic optimization
Role in the trial
Investigational active treatment arm
Blinded control arm serving as placebo comparator
Represents usual care patients would receive outside the device trial
Primary use
To promote healing of diabetic foot ulcers by combining light and magnetic stimulation
To serve as a visually similar placebo without therapeutic output
To facilitate wound healing through proven clinical practices
How it is given or performed
Applied locally to the ulcer via a sterile disposable base and secured with a strap to deliver optical and magnetic stimulation
Applied in the same manner but without therapeutic outputs to maintain blinding
Provided according to guideline‑based practices through debridement, offloading, infection control and metabolic support
Evidence status
Effectiveness is currently being evaluated; trial results are pending
Serves as control; no efficacy claims intended
Proven to aid healing when implemented as part of multidisciplinary DFU management
Important limitations
No efficacy or safety results available yet — efficacy is unproven
Designed only as placebo; does not provide therapeutic benefits
May not incorporate newer technologies like optical/magnetic stimulation
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 22Years - 90Years
All Genders
Eligibility Criteria
You may qualify if you...
Male or female aged between 22 and 90 years
Female participants who can become pregnant must agree to use acceptable birth control during the study
Ability to understand and sign informed consent and comply with study visits and treatment
Diagnosis of type 1 or type 2 diabetes mellitus
Presence of one full-thickness diabetic foot ulcer at or below the ankle (malleoli)
Wagner Grade 1 or 2 ulcer without bone exposure
At least 2 cm margin between target ulcer and other ulcers on the same foot
Ulcer duration more than 30 days but less than 52 weeks
Ulcer area between 0.5 and 25 cm2 at screening after debridement
Adequate blood flow to the affected limb as shown by specified vascular tests
You will not qualify if you...
Known pregnancy or currently breastfeeding
Active or history of skin cancer or other localized cancers in the treatment area
Taking medications that may affect ulcer healing as judged by the investigator
Current treatment for active systemic infection including bone infection (osteomyelitis)
Wagner Grade 3, 4, or 5 ulcers
Participation in another clinical trial with investigational drug or device within 30 days before or during this trial
Any health condition posing unreasonable risk as judged by the investigator
Chronic kidney failure requiring dialysis
Use of systemic corticosteroids above specified doses and durations
Significant wound healing before randomization as indicated by more than 30% or 50% ulcer closure during run-in phase
Abnormal blood chemistry or blood counts outside specified limits including albumin, kidney function, white blood cells, hemoglobin, neutrophils, platelets, or HbA1C above 12%
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Run-in Period
Duration - 2 to 4 weeks
Participants are observed for wound healing progress to determine eligibility before randomization.
Visits during this period to assess wound closure
Treatment
Duration - Up to 24 weeks
Participants receive treatment with either the active COMS One device or a sham device alongside standard care to promote wound healing.
Multiple visits through 24 weeks during treatment
Follow-up
Duration - Up to 24 weeks post-treatment start
Participants are monitored for safety, wound healing progress, quality of life, and pain assessment after treatment.
Visits at Week 1, Week 8, Week 12, Week 16, Week 20, and Week 24
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Tracking Healing Progress of Chronic Wounds Using Mepilex Up Dressing
For Venous Leg Ulcers and Diabetic Foot Ulcers in Adults
Follow-up Study Evaluating Safety of ALLO-ASC-DFU Treatment for Diabetic Foot Ulcer After Phase 3 Trial
A Phase 4 Multicenter Study Testing a Single-Layer Placental-Based Graft Plus Standard Care for Treating Nonhealing Diabetic Foot Ulcers
Phase 2a Study Evaluating Safety and Effectiveness of MDI-1228-mesylate Gel Plus Standard Care Versus Standard Care Alone in Adults With Diabetic Foot Ulcers
Evaluation of BIOxHEAL with Standard Care Versus Standard Care Alone for Nonhealing Diabetic Foot Ulcers in a Randomized Controlled Trial
Phase 3 Study of ENERGI-F703 GEL for Treating Diabetic Foot Ulcers
Randomized, Double-Blind, Vehicle-Controlled Parallel Trial
Evaluating Purified Native Type 1 Collagen Matrix with Polyhexamethylene Biguanide and Standard Care
Versus Standard Care Alone for Treating Chronic Diabetic Foot Ulcers
Lifestyle-Focused Offloading Treatment for Adults with Diabetic Foot Ulcers
Virtual Sessions Led by Occupational Therapists
Evaluating Topical BB-101 for Treating Diabetic Foot and Lower Leg Ulcers in a Randomized Controlled Trial
Study of Demographic, Clinical, and Laboratory Features in Patients with Diabetic Foot Ulcers at 5 Azar Hospital in 2024
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The trial design of the concurrent optical and magnetic stimulation (COMS) therapy study for refractory diabetic foot ulcers (MAVERICKS): a multicenter, randomized, sham-controlled, double-blind investigational device exemption clinical study.